Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya
© Thathy et al; licensee BioMed Central Ltd. 2005
Received: 09 August 2005
Accepted: 08 November 2005
Published: 08 November 2005
It has been hypothesized that the African alleles Sl2 and McC b of the Swain-Langley (Sl) and McCoy (McC) blood group antigens of the complement receptor 1 (CR1) may confer a survival advantage in the setting of Plasmodium falciparum malaria, but this has not been demonstrated.
To test this hypothesis, children in western Kenya with severe malaria-associated anaemia or cerebral malaria were matched to symptomatic uncomplicated malaria controls by age and gender. Swain-Langley and McCoy blood group alleles were determined by restriction fragment length polymorphism and conditional logistic regression was carried out.
No significant association was found between the African alleles and severe malaria-associated anaemia. However, children with Sl2/2 genotype were less likely to have cerebral malaria (OR = 0.17, 95% CI 0.04 to 0.72, P = 0.02) than children with Sl1/1. In particular, individuals with Sl2/2 McC a/b genotype were less likely to have cerebral malaria (OR = 0.18, 95% CI 0.04 to 0.77, P = 0.02) than individuals with Sl1/1 McC a/a .
These results support the hypothesis that the Sl2 allele and, possibly, the McC b allele evolved in the context of malaria transmission and that in certain combinations probably confer a survival advantage on these populations.
Plasmodium falciparum malaria is responsible for most of the more than one million deaths that occur each year from malaria infection in Africa . Most of these deaths occur as a result of complications such as severe malaria-associated anaemia (SMA) and cerebral malaria (CM) or coma . The pathogenesis of these complications is poorly understood. Evidence from several studies [3–7] suggests that the complement receptor 1 (CR1, CD35) may be involved in the pathogenesis of severe malaria. However, its exact role is not known.
The CR1 gene exhibits a number of polymorphisms. There are several size variants which are felt to be the result of unequal gene crossover . The most common variant has four LHRs (Figure 1). Polymorphisms that correlate with the quantitative expression of CR1 on erythrocytes of Caucasians but not of Africans have also been identified [14, 15]. Lastly, the Knops blood group antigens, including the Swain-Langley (Sl), McCoy (McC) and their alleles, have been localized to the CR1 protein in LHR-D [16–18].
The study of the Sl and McC blood group antigens may offer further clues as to the role of CR1 in the pathogenesis of severe malaria. The phenotypic absence of these antigens, designated Sl -1,2  and McC(a-b+) respectively, is occasionally the result of low CR1 copy numbers on the RBC or, most commonly, due to non-synonymous base substitutions . The alleles responsible for the phenotypic absence are very rare in ethnic groups that are not of African descent. Thus, this observation has led to the hypothesis that the Sl2 and McC b alleles may confer a survival advantage in the face of diseases such as malaria. In support of this hypothesis Sl -1,2 erythrocytes were found to rosette less in vitro than Sl 1,-2 erythrocytes . However, a recent study failed to reveal an association between Sl2 or McC b and resistance to severe malaria in The Gambia, West Africa . The present study describes the findings of an investigation designed to determine whether there is an association between resistance or susceptibility to severe malaria and the Sl and McC blood group alleles in western Kenya, a region of malaria endemicity. The findings suggest that, contrary to a previous report , Sl2 does confer an advantage in the setting of malaria infection.
Populations and study design
Participants were recruited under human use protocols approved by the Human Subjects Research Review Board, Office of the Surgeon General, US Army, and the Ethics Review Committee of the Kenya Medical Research Institute, Nairobi, Kenya. All procedures were in accordance with the Helsinki Declaration. The study had a matched case-control design. The demographics of some of the study participants as well as the inclusion/exclusion criteria have been described before [5–7]. SMA cases, defined as children with asexual P. falciparum parasitaemia by Giemsa-stained thick and thin blood smear and Hb ≤ 5 g/dL, were recruited from the pediatric ward of the Nyanza Provincial General Hospital (NPGH), Kisumu, Kenya. The NPGH catchment area is the malaria holoendemic region of the Lake Victoria basin in western Kenya, where most individuals are of the Luo ethnic group. Because CM is uncommon in the Lake Victoria basin, CM cases were recruited from the pediatric ward of the Kisii District Hospital (KDH), as well as from the NPGH. KDH is located in the highlands of western Kenya where transmission is seasonal and consequently receives many more CM cases than the NPGH . The predominant ethnic group in Kisii is the Abagusii. CM was defined as asexual P. falciparum parasitaemia by Giemsa-stained blood smear and a Blantyre coma score of ≤ 2 , lasting at least 30 min if there was a history of convulsions. One control with symptomatic uncomplicated malaria was matched to each case by age ± two months and gender and was identified from the outpatient clinic of the same hospital where the corresponding case was obtained. Symptomatic uncomplicated malaria was defined as a Giemsa-stained blood smear positive for asexual P. falciparum and an axillary temperature ≥ 37.5°C or, in the absence of the latter, two of the following signs or symptoms: nausea/vomiting, irritability, poor feeding, myalgias or headache. Children were excluded from participation if there was evidence of other concomitant serious infections (i.e. meningitis excluded by lumbar puncture, pneumonia, sepsis) or chronic illness. All children with suspected CM underwent a lumbar puncture to exclude meningitis and were enrolled if the results of Gram stain and culture were negative. In addition, because some of our studies also included the measurement of erythrocyte complement regulatory proteins, children were excluded if they had a history of blood transfusion in the three months preceding enrolment to avoid the influence of donor erythrocytes.
Genotyping of CR1 Knops blood group polymorphisms
A whole blood sample obtained at enrolment, and prior to any blood transfusion, was used to extract DNA and/or blotted onto filter papers for later extraction. Personnel who were unaware of the group assignments of the study participants carried out DNA extraction, amplification and interpretation of restriction fragment length polymorphisms (RFLPs) patterns. DNA was extracted from whole blood using the QIAamp DNA blood extraction protocol (Qiagen, Valencia, CA). DNA extraction from filter papers was performed using saponin and Chelex as previously described . Once extracted, genomic DNA was stored frozen at -20°C for later analysis. The Sl1/Sl2 and McC a /McC b Knops blood group alleles result from single nucleotide polymorphisms that cause specific amino acid changes in exon 29 (encoding CCP 25; Figure 1). An established PCR-RFLP method was used for the detection of both SNPs . Briefly, the oligonucleotide forward primer 24KnNde: 5'-ACC AGT GCC ACA CTG GAC CAG ATG GAG AAC AGC TGT TTG AGC AT-3' and reverse primer 25Rb: 5'-GGA GGA GTG TGG CAG CTT G-3', were used to amplify a 305 bp fragment of CR1 exon 29 by PCR. The amplification reactions were carried out on ~500 ng of genomic DNA in a 100 μl final volume containing 1× GeneAmp PCR Buffer II (Applied Biosystems, Foster City, CA), 2.5 mM MgCl2, 200 μM each dNTP, 0.2 μM each primer and 5 U AmpliTaq Gold® DNA Polymerase (Applied Biosystems, Foster City, CA). After 9 min of initial denaturation at 95°C, the thermocycling program used consisted of 1 min denaturation at 94°C, 1 min annealing at 58°C, and 1 min extension at 72°C for 44 cycles, followed by a final extension of 10 min at 72°C. For RFLP analysis, 28 μL of each PCR product was digested with either Mfe I (New England Biolabs, Beverly, MA), for the detection of Sl1/Sl2, or Bsm I (New England Biolabs), for the detection of McC a /McC b , and the restriction fragments were resolved by agarose gel electrophoresis as previously described .
All analyses were done using SPSS version 11.5 (SPSS Inc., Chicago, IL). Chi-square tests were performed to compare the observed and predicted frequencies of genotypes based on allelic frequencies in different ethnic groups. Conditional logistic regression based on matched pairs and adjusted for ethnic groups was carried out for each single locus (Sl and McC) and for the combination of the two loci. Thus, each regression model included terms both for genotype and ethnic group. All tests were two-sided with α = 0.05.
Nyanza Provincial General Hospital N = 320
Kisii District Hospital N = 140
Cases N = 137
Controls N = 137
Cases N = 23
Controls N = 23
Cases N = 70
Controls N = 70
Mean age in months (SD)
No. of females (%)
Ethnic groups (%)
Percent of Swain-Langley and McCoy genotypes in various populations.
Western Kenya N = 460
The Gambia N = 853
Mali N = 99
Caucasian Americans N = 100
Asian Americans N = 99
Hispanic Americans N = 100
Sl2/2 is associated with decreased susceptibility to cerebral malaria
Conditional logistic regression based on matching to compare individual genotypes.
No. of cases (%)
No. of controls (%)
No. of cases (%)
No. of controls (%)
0.24 to 4.93
0.12 to 2.05
0.14 to 3.06
0.04 to 0.72
0.41 to 2.11
0.55 to 3.52
0.29 to 6.57
0.43 to 29.06
Sl2/2 McC a/b genotype is associated with decreased susceptibility to cerebral malaria
Conditional logistic regression to compare genotype combinations to the non-African genotype Sl1/1 McC a/a .
No. of cases (%)
No. of controls (%)
No. of cases (%)
No. of controls (%)
0.20 to 4.37
0.09 to 1.77
0.17 to 4.43
0.05 to 1.19
0.12 to 2.34
0.04 to 0.77
0.26 to 5.40
0.19 to 4.60
0.15 to 5.14
0.07 to 6.07
The present study has shown that individuals with the Sl2/2 genotype that confers the Sl -1,2 phenotype have decreased susceptibility to CM compared to individuals with the Sl1/1 genotype. This finding was independent of ethnicity, of the genotype at the McC locus and of the hospital site where the cases and controls were recruited. Among the combined genotypes, a trend of increasing benefit was observed in the background of McC a/a from Sl1/2 to Sl2/2, which is consistent with a gene dose effect. Although the level of statistical significance may be influenced by a larger sample size in the Sl2/2 category, the association nevertheless appears strongest with the acquisition of one McC b allele (Table 4).
The finding that genotype Sl2/2 McC a/b might be the one that most influences the level of susceptibility to CM may seem counterintuitive since in Table 3 McC a/b did not show any significant advantage and perhaps showed a trend towards a detrimental effect relative to McC a/a . However, in the analysis in Table 3 the reference genotype McC a/a contains three variants: Sl1/1 McC a/a , Sl1/2 McC a/a , and Sl2/2 McC a/a with the latter two both showing indications of decreased susceptibility due to the presence of Sl2 (Table 4). The lack of significant benefit from Sl2/2 in SMA probably reflects the distinct pathogenic mechanisms between this condition and CM, but this does not exclude a role for CR1 in the pathogenesis of SMA.
In contrast to this study, a previous case-control study in The Gambia  failed to demonstrate any significant association between Sl2/2 and resistance to severe malaria. The divergence in findings between the present and the previous study could be explained by important methodological differences. In the Gambian study controls did not have malaria. This may have led to an overrepresentation of non-protective genotypes in the controls because these children did not have the most important risk factor for severe malaria, i.e. malaria. Further, cases and controls were not matched by age in the Gambian study, and in fact, cases were older than controls by an average of almost one year. In addition, it is possible that differences in the pathogenesis of severe malaria between the two sites on the basis of other genetic factors and/or differences in the malaria transmission patterns may exist.
The mechanism by which the Sl2 and McC b alleles could confer protection from severe malaria is not known, since these polymorphisms are located near the C-terminus of the CR1 molecule in an area that is outside the binding sites for C3b, C4b, and PfEMP-1. Nonetheless, there are a number of potential explanations based on the knowledge of CR1 function and the nature of the amino acid substitutions that take place. The Sl2 allele is the result of the substitution of glycine, a neutral amino acid, for the basic amino acid arginine at position 1601 (R1601G), whereas the McC b allele is the result of the substitution of the acidic amino acid glutamic acid for the basic amino acid lysine at position 1590 (K1590E) . These modifications may inflict significant conformational or charge changes to the rest of the molecule and may consequently impact on the conformation and function of the C3b and C4b binding sites and/or the PfEMP-1 binding site. Accordingly, Sl -1,2 erythrocytes have been reported to rosette less than Sl 1,-2 erythrocytes . In addition, it is known that CR1 molecules are aggregated on the erythrocyte surface and this aggregation is felt to be critical to the binding affinity of CR1 for C3b and C4b . Therefore, it is possible that the amino acid substitutions not only induce conformational changes to the individual CR1 molecules but also affect the ability of functional aggregates to form due to conformational incompatibility or charge interference between different CR1 molecules. This could explain why some combinations of these alleles, such as heterozygosity at both loci or homozygosity for both Sl2 and McC b , did not offer any significant advantage.
Although the current expectation is that CR1 may influence the development of severe malaria by virtue of its function as a regulator of the complement cascade on RBCs or by its direct interaction with the infected RBCs leading to rosette formation, CR1 may exert its effect on malaria in other ways that are not yet understood. In addition to being present on RBCs, CR1 is also present on follicular dendritic cells, macrophages and T and B lymphocytes and, therefore, may also have immunoregulatory functions that affect the development of immunity against malaria . Mice deficient in CR1/CR2 have depressed humoral immune responses . Further studies will be required to explore this possibility.
Further evidence that the role of CR1 in the pathogenesis of severe malaria may not be as expected is found in a recent case-control study in Papua New Guinea that aimed to determine whether there was an association between individuals who had the low CR1 expression allele (L) and resistance to severe malaria . Contrary to expectation, the association was found only in heterozygotes (HL), and not in homozygotes (LL), which presumably had the lowest CR1 levels. In addition, although there was an association with resistance to severe malaria as a whole, there was no apparent association between these polymorphisms and CM. These results suggest that the relationship between the number of CR1 molecules on the RBC surface and severe malaria is not a straightforward one.
The results obtained in the study presented here have biological significance and are further supportive evidence of the importance of CR1 in the pathogenesis of severe malaria. Whatever the mechanism is by which CR1 is involved in the pathogenesis of malaria, knowledge of which alleles are associated with resistance or susceptibility to severe malaria will make it possible to observe the relationship between structure and function and susceptibility to severe malaria.
The results support the conclusion that the Sl2 allele and, possibly, the McC b allele have evolved in the context of malaria transmission in Africa and that in certain combinations probably confer a survival advantage to malaria endemic populations.
We would like to thank the children who participated in our studies as well as their parents for their willingness to contribute to this research endeavor. We are indebted to our dedicated staff of clinicians, nurses, drivers and field workers who made these studies possible. We are also grateful to Dr. John Rowlands for statistical support and for reviewing the paper. This work is published with the permission of the Office of the Director, the Kenya Medical Research Institute.
This work was supported in part by the US Army Medical Research and Materiel Command, by grants from the National Heart Lung and Blood Institute (RO1 HL 7502-01) to José A. Stoute and from the National Institute of Allergy and Infectious Diseases (RO1 AI 42367) to Joann M. Moulds. Vandana Thathy was supported by a fellowship from the Ellison Medical Foundation and the National Research Council. Bernard Guyah and Walter Otieno were supported by a training grant from the Fogarty International Center (1 D43 TW06239-01). Funding agencies had no role in the design of the study, the data collection, data analysis, data interpretation, writing of the manuscript, nor in the decision to submit the manuscript for publication.
"The views of the authors do not purport to reflect the position of the Department of the Army or the Department of Defense. The U.S. Government has the right to retain a nonexclusive, royalty-free license in and to any copyright covering this paper."
- Organization WH: World Health Report. 2002, Geneva, WHOGoogle Scholar
- Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000, 94 Suppl 1: S1-90.
- Rowe JA, Moulds JM, Newbold CI, Miller LH: P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature. 1997, 388: 292-295. 10.1038/40269.View ArticlePubMedGoogle Scholar
- Rowe JA, Rogerson SJ, Raza A, Moulds JM, Kazatchkine MD, Marsh K, Newbold CI, Atkinson JP, Miller LH: Mapping of the region of complement receptor (CR) 1 required for Plasmodium falciparum rosetting and demonstration of the importance of CR1 in rosetting in field isolates. J Immunol. 2000, 165: 6341-6346.View ArticlePubMedGoogle Scholar
- Waitumbi JN, Opollo MO, Muga RO, Misore AO, Stoute JA: Red cell surface changes and erythrophagocytosis in children with severe Plasmodium falciparum anemia. Blood. 2000, 95: 1481-1486.PubMedGoogle Scholar
- Stoute JA, Odindo AO, Owuor BO, Mibei EK, Opollo MO, Waitumbi JN: Loss of red blood cell complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia. J Infect Dis. 2003, 187: 522-525. 10.1086/367712.View ArticlePubMedGoogle Scholar
- Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-related changes in red blood cell complement regulatory proteins and the susceptibility to severe malaria. J Infect Dis. 2004, 190: 1183-1191. 10.1086/423140.View ArticlePubMedGoogle Scholar
- Krych-Goldberg M, Atkinson JP: Structure-function relationships of complement receptor type 1. Immunol Rev. 2001, 180: 112-122. 10.1034/j.1600-065X.2001.1800110.x.View ArticlePubMedGoogle Scholar
- Ghiran I, Barbashov SF, Klickstein LB, Tas SW, Jensenius JC, Nicholson-Weller A: Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med. 2000, 192: 1797-1808. 10.1084/jem.192.12.1797.PubMed CentralView ArticlePubMedGoogle Scholar
- Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A: Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity. 1997, 7: 345-355. 10.1016/S1074-7613(00)80356-8.View ArticlePubMedGoogle Scholar
- Carlson J, Helmby H, Hill AV, Brewster D, Greenwood BM, Wahlgren M: Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. Lancet. 1990, 336: 1457-1460. 10.1016/0140-6736(90)93174-N.View ArticlePubMedGoogle Scholar
- Rowe A, Obeiro J, Newbold CI, Marsh K: Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infect Immun. 1995, 63: 2323-2326.PubMed CentralPubMedGoogle Scholar
- Ahearn JM, Fearon DT: Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol. 1989, 46: 183-219.View ArticlePubMedGoogle Scholar
- Herrera AH, Xiang L, Martin SG, Lewis J, Wilson JG: Analysis of complement receptor type 1 (CR1) expression on erythrocytes and of CR1 allelic markers in Caucasian and African American populations. Clin Immunol Immunopathol. 1998, 87: 176-183. 10.1006/clin.1998.4529.View ArticlePubMedGoogle Scholar
- Rowe JA, Raza A, Diallo DA, Baby M, Poudiougo B, Coulibaly D, Cockburn IA, Middleton J, Lyke KE, Plowe CV, Doumbo OK, Moulds JM: Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans; implications for studies on malaria susceptibility. Genes Immun. 2002, 3: 497-500. 10.1038/sj.gene.6363899.View ArticlePubMedGoogle Scholar
- Moulds JM, Nickells MW, Moulds JJ, Brown MC, Atkinson JP: The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-langley, and York blood group antisera. J Exp Med. 1991, 173: 1159-1163. 10.1084/jem.173.5.1159.View ArticlePubMedGoogle Scholar
- Moulds JM, Zimmerman PA, Doumbo OK, Kassambara L, Sagara I, Diallo DA, Atkinson JP, Krych-Goldberg M, Hauhart RE, Hourcade DE, McNamara DT, Birmingham DJ, Rowe JA, Moulds JJ, Miller LH: Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1. Blood. 2001, 97: 2879-2885. 10.1182/blood.V97.9.2879.View ArticlePubMedGoogle Scholar
- Rao N, Ferguson DJ, Lee SF, Telen MJ: Identification of human erythrocyte blood group antigens on the C3b/C4b receptor. J Immunol. 1991, 146: 3502-3507.PubMedGoogle Scholar
- Daniels GL, Cartron JP, Fletcher A, Garratty G, Henry S, Jorgensen J, Judd WJ, Levene C, Lin M, Lomas-Francis C, Moulds JJ, Moulds JM, Moulds M, Overbeeke M, Reid ME, Rouger P, Scott M, Sistonen P, Smart E, Tani Y, Wendel S, Zelinski T: International Society of Blood Transfusion Committee on terminology for red cell surface antigens: Vancouver Report. Vox Sang. 2003, 84: 244-247. 10.1046/j.1423-0410.2003.00282.x.View ArticlePubMedGoogle Scholar
- Zimmerman PA, Fitness J, Moulds JM, McNamara DT, Kasehagen LJ, Rowe JA, Hill AV: CR1 Knops blood group alleles are not associated with severe malaria in the Gambia. Genes Immun. 2003, 4: 368-373. 10.1038/sj.gene.6363980.PubMed CentralView ArticlePubMedGoogle Scholar
- Marsh K, Snow RW: Malaria transmission and morbidity. Parassitologia. 1999, 41: 241-246.PubMedGoogle Scholar
- Molyneux ME, Taylor TE, Wirima JJ, Borgstein A: Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med. 1989, 71: 441-459.PubMedGoogle Scholar
- Farnert A, Arez AP, Correia AT, Bjorkman A, Snounou G, do Rosario V: Sampling and storage of blood and the detection of malaria parasites by polymerase chain reaction. Trans R Soc Trop Med Hyg. 1999, 93: 50-53. 10.1016/S0035-9203(99)90177-3.View ArticlePubMedGoogle Scholar
- Moulds JM, Thomas BJ, Doumbo O, Diallo DA, Lyke KE, Plowe CV, Rowe JA, Birmingham DJ: Identification of the Kna/Knb polymorphism and a method for Knops genotyping. Transfusion. 2004, 44: 164-169. 10.1111/j.1537-2995.2004.00615.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Paccaud JP, Carpentier JL, Schifferli JA: Difference in the clustering of complement receptor type 1 (CR1) on polymorphonuclear leukocytes and erythrocytes: effect on immune adherence. Eur J Immunol. 1990, 20: 283-289.View ArticlePubMedGoogle Scholar
- Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD: Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A. 1996, 93: 3357-3361. 10.1073/pnas.93.8.3357.PubMed CentralView ArticlePubMedGoogle Scholar
- Cockburn IA, Mackinnon MJ, O'Donnell A, Allen SJ, Moulds JM, Baisor M, Bockarie M, Reeder JC, Rowe JA: A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci U S A. 2004, 101: 272-277. 10.1073/pnas.0305306101.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.